Their approach combined two levels of data: interactions between single zinc fingers and DNA, and between each zinc finger and its neighbouring finger. These zinc finger pair interactions influence ...

Zinc is “the Barry Manilow of heavy metals—really dull and really boring. It’s not fancy, like iron or copper.” But as Adrian Woolfson, BM BCh PhD, reaches his first-year anniversary as Sangamo’s ...

Sangamo Therapeutics researchers illustrated the linkers and architectures they developed in a study published today in Nature Communications. The study detailed the latest improvements incorporated ...

Novartis is the latest big drug firm to strike a collaboration with Sangamo Therapeutics. The two firms will develop therapies based on Sangamo’s zinc finger technology that targets genes linked to ...

An artificial intelligence (AI) program may enable the first simple production of customizable proteins called zinc fingers to treat diseases by turning genes on and off. The researchers at NYU ...

Figure 1: Structure and selection of phage displayed zinc fingers. Figure 2: Compilation of α-helix amino acid sequences of selected zinc fingers. Figure 4: Selected zinc finger peptide binding to RRE ...

Zinc finger nucleases are designed to be like heat-seeking missiles, precisely targeted to find and cut specific sequences of DNA. Occasionally, however, they may snip the wrong spot, causing ...

Biogen is making a big bet on gene therapies for neurodegenerative diseases. The firm will pay Sangamo Therapeutics $350 million upfront to develop zinc finger gene therapies for Alzheimer’s disease, ...

If you're an investor who's heard of zinc-finger proteins and gene editing but you aren't sure what it all means, this can help answer your questions. There are 350 million people worldwide with rare ...

Genome editing is making inroads into biomedical research and medicine. By employing biomolecule modeling tools, a Japanese research team is accelerating the pace and cutting the cost of zinc finger ...

Researchers have, for the first time, modified a single, disease-causing mutation without altering any other parts of the genome in human stem cells. Scientists in Rudolph Jaenisch’s lab at the ...